Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
NEXNF$0.09-0.00(-2.45%)NEXE Innovations Reports Q1 Fiscal 2027 Results and Business Update[8:03:56 PM ET]UREKF$0.120.00(0.00%)Eureka Metals Corp. Announces Rights Offering and Proposed Share Consolidation[7:57:00 PM ET]RMBI$15.860.00(0.00%)RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES 2026 THIRD QUARTER FINANCIAL RESULTS Richmond Mutual Bancorporation, Inc., a Maryland corporation (the "Company") (NASDAQ: RMBI), parent company of First Bank Midwest, today reported net ...[7:55:00 PM ET]MVLY$21.69+0.73(+3.48%)Mission Valley Bancorp Reports Third Quarter Results[7:52:00 PM ET]UNIB$21.350.00(0.00%)University Bancorp Closes on the Acquisition of 20% of UIF Corporation for Cash & Stock Worth About $15.2 Million[7:45:00 PM ET]NXTT$5.02+0.17(+3.51%)Next Technology Holding Inc. Announces Board Authorization to Sell or Pledge of Bitcoin Holdings to Reduce Bitcoin Exposure and Enhance Liquidity[7:20:00 PM ET]PRRSF$0.04+0.00(+10.13%)Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement[6:35:00 PM ET]OTAI$10.11+0.00(+0.05%)Spider Digital Technology Ltd. and Starlink AI Acquisition Corporation Announce Definitive Business Combination Agreement[6:30:00 PM ET]REVVF$0.170.00(0.00%)Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario[6:30:00 PM ET]CTSH$64.90+2.38(+3.81%)Cognizant setzt mehr als 25.000 Fachkräfte für die Umsetzung von OpenAI-Lösungen ein, während Unternehmen bahnbrechende KI-Technologien in die Produktion überführen Cognizant (Nasdaq: CTSH) gab heute die Gründung seiner „OpenAI Frontier Capability Group" bekannt, in der mehr als 25.000 Fachkräfte zusammenkommen,...[6:17:00 PM ET]INO$2.06+1.29(+166.91%)INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...[6:01:00 PM ET]KVUE$19.31-0.25(-1.28%)Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on...[5:51:00 PM ET]

ADMA · NASDAQ

ADMA Biologics, Inc.

$11.25 +0.48 (+4.21%)

Company overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.5B
Employees
685
Headquarters
Ramsey, NJ
Website
admabiologics.com
CEO
Adam S. Grossman
Listed
October 17, 2013
P/E
16.30
Dividend yield
0.00%

Company financials

Revenue
$510M
Gross profit
$312M
Operating income
$207M
EBITDA
$213M
Net income
$165M
EPS
$0.69
Total assets
$665M
Total debt
$204M
Gross margin
61.28%
Net margin
32.43%
Earnings yield
6.13%

Revenue segmentation

By product (FY 2025)

No annual product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

7.278.479.6710.8712.07
ADMA 1D NASDAQ O11.83H11.89L11.37C11.39-0.37 (-3.11%)Vol462.47K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ADMAADMA Biologics, Inc. Stock news Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know Zacks Investment Research
ADMAADMA Biologics, Inc. Press release ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 GlobeNewswire
ADMAADMA Biologics, Inc. Press release ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process GlobeNewswire
ADMAADMA Biologics, Inc. Stock news Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Moderate Buy” from Analysts Defense World
ADMAADMA Biologics, Inc. Stock news Here's Why Adma Biologics (ADMA) Fell More Than Broader Market Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Why Adma Biologics (ADMA) Dipped More Than Broader Market Today Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research
ADMAADMA Biologics, Inc. Legal Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Newsfile Corp
ADMAADMA Biologics, Inc. Stock news Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks Investment Research
ADMAADMA Biologics, Inc. Stock news Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? Zacks Investment Research
ADMAADMA Biologics, Inc. Legal Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PR Newswire
ADMAADMA Biologics, Inc. Stock news Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? Zacks Investment Research
ADMAADMA Biologics, Inc. Legal ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty Newsfile Corp
ADMAADMA Biologics, Inc. Legal Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Newsfile Corp
See more
FAQ

Questions about ADMA Biologics, Inc.

What does ADMA Biologics, Inc. do?
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
What is ADMA's market cap?
ADMA Biologics, Inc. (ADMA) is a listed stock with a live quote. The latest market cap on this page is $2.5B.
Where is ADMA Biologics, Inc. headquartered?
ADMA Biologics, Inc. is headquartered in Ramsey, NJ.
How do I get ADMA news from the API?
Call GET /v1/news?tickers=ADMA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ADMA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ADMA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ADMA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs